Boris P Hejblum1, Jing Cui2, Lauren J Lahey3, Andrew Cagan4, Jeffrey A Sparks2, Jeremy Sokolove3, Tianxi Cai5, Katherine P Liao2. 1. Harvard T. H. Chan School of Public Health, Boston, Massachusetts, and University of Bordeaux, ISPED, INSERM Bordeaux Population Health U1219, Bordeaux, France. 2. Brigham and Women's Hospital, Boston, Massachusetts. 3. VA Palo Alto Healthcare System and Stanford University School of Medicine, Palo Alto, California. 4. Partners Healthcare, Boston, Massachusetts. 5. Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Abstract
OBJECTIVE: Antibodies against citrullinated fibrinogen (anti-Cit-fibrinogen) have been implicated in rheumatoid arthritis (RA) and associated with cardiovascular risk in RA. The objective of this study was to examine the association between anti-Cit-fibrinogens and coronary artery disease (CAD) outcomes. METHODS: We performed the study in an RA cohort based in a large academic institution linked with electronic medical record data containing information on CAD outcomes from medical record review. Using a published bead-based assay method, we measured 10 types of anti-Cit-fibrinogens. We applied a score test to determine the association between the anti-Cit-fibrinogens as a group with CAD outcomes. Principal components analysis (PCA) was performed to assess whether the anti-Cit-fibrinogens clustered into groups. Each group was then additionally tested for association with CAD. Sensitivity analyses were also performed using a published International Classification of Disease, Ninth Revision code group for ischemic heart disease (IHD) as the outcome. RESULTS: We studied 1,006 RA subjects (mean ± SD age 61.0 ± 13.0 years; 72.2% anti-cyclic citrullinated peptide positive). As a group, anti-Cit-fibrinogen was associated with CAD (P = 1.1 × 10-4 ). From the PCA analysis, we observed 3 main groups, of which only 1 group, containing 7 of the 10 anti-Cit-fibrinogens, was significantly associated with CAD outcomes (P = 0.015). In the sensitivity analysis, all anti-Cit-fibrinogens as a group remained significantly associated with IHD (P = 2.9 × 10-4 ). CONCLUSION: Anti-Cit-fibrinogen antibodies as a group were associated with CAD outcomes in our RA cohort, with the strongest signal for association arising from a subset of the autoantibodies.
OBJECTIVE: Antibodies against citrullinated fibrinogen (anti-Cit-fibrinogen) have been implicated in rheumatoid arthritis (RA) and associated with cardiovascular risk in RA. The objective of this study was to examine the association between anti-Cit-fibrinogens and coronary artery disease (CAD) outcomes. METHODS: We performed the study in an RA cohort based in a large academic institution linked with electronic medical record data containing information on CAD outcomes from medical record review. Using a published bead-based assay method, we measured 10 types of anti-Cit-fibrinogens. We applied a score test to determine the association between the anti-Cit-fibrinogens as a group with CAD outcomes. Principal components analysis (PCA) was performed to assess whether the anti-Cit-fibrinogens clustered into groups. Each group was then additionally tested for association with CAD. Sensitivity analyses were also performed using a published International Classification of Disease, Ninth Revision code group for ischemic heart disease (IHD) as the outcome. RESULTS: We studied 1,006 RA subjects (mean ± SD age 61.0 ± 13.0 years; 72.2% anti-cyclic citrullinated peptide positive). As a group, anti-Cit-fibrinogen was associated with CAD (P = 1.1 × 10-4 ). From the PCA analysis, we observed 3 main groups, of which only 1 group, containing 7 of the 10 anti-Cit-fibrinogens, was significantly associated with CAD outcomes (P = 0.015). In the sensitivity analysis, all anti-Cit-fibrinogens as a group remained significantly associated with IHD (P = 2.9 × 10-4 ). CONCLUSION: Anti-Cit-fibrinogen antibodies as a group were associated with CAD outcomes in our RA cohort, with the strongest signal for association arising from a subset of the autoantibodies.
Authors: Justin M Kollman; Leela Pandi; Michael R Sawaya; Marcia Riley; Russell F Doolittle Journal: Biochemistry Date: 2009-05-12 Impact factor: 3.162
Authors: Cynthia S Crowson; Eric L Matteson; Veronique L Roger; Terry M Therneau; Sherine E Gabriel Journal: Am J Cardiol Date: 2012-04-20 Impact factor: 2.778
Authors: Jeremy Sokolove; Matthew J Brennan; Orr Sharpe; Lauren J Lahey; Amy H Kao; Eswar Krishnan; Daniel Edmundowicz; Christin M Lepus; Mary Chester Wasko; William H Robinson Journal: Arthritis Rheum Date: 2013-07
Authors: Ariana Montes; Alfonso Corrales; Manuel Calaza; Raquel Lopez-Mejias; Jose A Parra; Miguel A González-Gay; Antonio González Journal: Arthritis Rheumatol Date: 2015-11 Impact factor: 10.995
Authors: Joshua C Denny; Lisa Bastarache; Marylyn D Ritchie; Robert J Carroll; Raquel Zink; Jonathan D Mosley; Julie R Field; Jill M Pulley; Andrea H Ramirez; Erica Bowton; Melissa A Basford; David S Carrell; Peggy L Peissig; Abel N Kho; Jennifer A Pacheco; Luke V Rasmussen; David R Crosslin; Paul K Crane; Jyotishman Pathak; Suzette J Bielinski; Sarah A Pendergrass; Hua Xu; Lucia A Hindorff; Rongling Li; Teri A Manolio; Christopher G Chute; Rex L Chisholm; Eric B Larson; Gail P Jarvik; Murray H Brilliant; Catherine A McCarty; Iftikhar J Kullo; Jonathan L Haines; Dana C Crawford; Daniel R Masys; Dan M Roden Journal: Nat Biotechnol Date: 2013-12 Impact factor: 54.908
Authors: Cátia Fernandes-Cerqueira; Elena Ossipova; Sunithi Gunasekera; Monika Hansson; Linda Mathsson; Anca I Catrina; Yngve Sommarin; Lars Klareskog; Karin Lundberg; Johan Rönnelid; Ulf Göransson; Per-Johan Jakobsson Journal: Arthritis Res Ther Date: 2015-06-10 Impact factor: 5.156
Authors: Mikael Brink; Monika Hansson; Linda Mathsson-Alm; Priyantha Wijayatunga; Marije K Verheul; Leendert A Trouw; Rikard Holmdahl; Johan Rönnelid; Lars Klareskog; Solbritt Rantapää-Dahlqvist Journal: Arthritis Res Ther Date: 2016-02-09 Impact factor: 5.156
Authors: Reinout Raijmakers; Joyce J B C van Beers; Mahmoud El-Azzouny; Natasja F C Visser; Borut Božič; Ger J M Pruijn; Albert J R Heck Journal: Arthritis Res Ther Date: 2012-05-14 Impact factor: 5.156
Authors: Katherine P Liao; Ashwin N Ananthakrishnan; Vishesh Kumar; Zongqi Xia; Andrew Cagan; Vivian S Gainer; Sergey Goryachev; Pei Chen; Guergana K Savova; Denis Agniel; Susanne Churchill; Jaeyoung Lee; Shawn N Murphy; Robert M Plenge; Peter Szolovits; Isaac Kohane; Stanley Y Shaw; Elizabeth W Karlson; Tianxi Cai Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240
Authors: Vanessa L Kronzer; Liwei Wang; Hongfang Liu; John M Davis; Jeffrey A Sparks; Cynthia S Crowson Journal: J Am Med Inform Assoc Date: 2020-04-01 Impact factor: 4.497